CA-CONFLUENT
12.5.2021 09:02:04 CEST | Business Wire | Press release
Confluent, Inc. , the platform to set data in motion, today announced Confluent for Kubernetes , the first platform purpose-built to bring cloud-native capabilities to data streams in private infrastructures. To make it easier and faster to harness the value of data in motion across an entire organization, Confluent drew on its expertise managing thousands of Apache Kafka® clusters in Confluent Cloud to offer the same cloud-native experience for on-premises environments. These cloud-native capabilities are key to running modern data platforms and are now available wherever an organization’s applications and data reside. Within minutes, it’s now possible to build a private cloud Kafka service that powers applications that are increasingly critical to how organizations thrive.
To win in today’s global economy, organizations must deliver exceptional customer experiences and data-driven, backend operations. This requires the ability to react, respond, and adapt to a continuous, ever-changing flow of data from across an organization in real time. This has driven the rapid rise of Kafka as a key enabler to helping companies cut across silos and process the flow of business events as they happen. However, given the high level of technical complexity, need for constant monitoring, and time-consuming custom tooling, self-managing Kafka is difficult and often takes large teams of specialized professionals. These challenges can result in costly project delays and inefficient resource investments, holding organizations back as they compete to innovate and win in a digital-first world.
“To compete in the digital realm, organizations need to quickly deliver personalized customer experiences and real-time operations, which are only possible with access to data from all environments and cloud-native advantages,” said Ganesh Srinivasan, Chief Product and Engineering Officer, Confluent. “For organizations that need to operate on premises, we’re bringing the benefits of cloud computing to their private infrastructure with Confluent for Kubernetes. Now, any company can build a private cloud service to move data across their business regardless of its environment.”
Confluent for Kubernetes – Bringing Benefits From the Leading Data in Motion Cloud Platform to On-Premises Environments
With the launch of Confluent for Kubernetes, Confluent brings together the cloud-native advantages learned from Confluent Cloud with the control and customization from self-managing their private infrastructure in on-premises environments. So whether an organization is transitioning to the cloud or needs to keep workloads on premises, they can take full advantage of Confluent for Kubernetes’ cloud-native capabilities, including a declarative API to deploy and operate Confluent. The platform also makes moving applications to the public cloud easier by seamlessly migrating workloads to wherever your business needs them with the ability to connect and share data with Confluent Cloud. By reimagining what is possible for private infrastructure with the capabilities of modern cloud computing, it is easier than ever for organizations to build and manage a private cloud Kafka service for moving data across a business.
- Enhanced reliability – As a cloud-native system, Confluent for Kubernetes intelligently detects if a process fails and will automatically restart processes or reschedule as necessary. Automated rack awareness spreads replicas of a partition across different racks, improving the availability of your brokers and limiting the risk of data loss. With automated reliability, organizations can minimize the risk of business disruption, reduce downtime costs, and limit data loss.
- Automated elasticity – Meet changing business demands with the ability to scale up using API-driven operations. The platform will automatically generate configurations, schedule and run new broker processes, and ensure data is balanced across brokers so that clusters can be efficiently utilized. With the ability to spin up and down Confluent clusters, organizations can control infrastructure costs while quickly scaling to meet their business needs.
- Simplified infrastructure management – A core concept of the cloud-native paradigm is the ability to focus on higher value activities that create business value rather than performing complex sequences of low-level infrastructure-related operations. Confluent for Kubernetes extends the Kubernetes API, enabling organizations to define the desired high-level state of clusters rather than manage all the low-level details. This infrastructure-as-code approach reduces operational burden and achieves a faster time to value, while enhancing security with standards that can be easily and consistently deployed across an organization.
Kafka Summit Europe 2021
Tune into Confluent Co-founder and CEO Jay Kreps’ keynote at Kafka Summit Europe on May 12 at 8:00 a.m. GMT to learn more about today’s news. Register now: https://kafkasummit.io/
For a deep dive into Confluent for Kubernetes, don’t miss this Kafka Summit Europe lightning talk happening today at 1 p.m. GMT: https://www.kafka-summit.org/sessions/gitops-for-kafka-with-confluent-for-kubernetes
Additional Resources
- For more details on how Confluent for Kubernetes works, check out our blog: https://www.confluent.io/blog/confluent-for-kubernetes-offers-cloud-native-kafka-automation/
- See how Confluent is helping its customers transform their businesses: https://www.confluent.io/customers/
- Learn more about Confluent: https://www.confluent.io/
- Join Confluent and apply for one of its open positions: https://www.confluent.io/careers/
About Confluent
Confluent is pioneering a fundamentally new category of data infrastructure focused on data in motion. Confluent’s cloud-native offering is the foundational platform for data in motion – designed to be the intelligent connective tissue enabling real-time data, from multiple sources, to constantly stream across the organization. With Confluent, organizations can meet the new business imperative of delivering rich, digital front-end customer experiences and transitioning to sophisticated, real-time, software-driven backend operations. To learn more, please visit www.confluent.io .
The preceding outlines our general product direction and is not a commitment to deliver any material, code, or functionality. The development, release, timing, and pricing of any features or functionality described may change. Customers should make their purchase decisions based upon services, features, and functions that are currently available. Confluent and associated marks are trademarks or registered trademarks of Confluent, Inc.
Apache® and Apache Kafka® are either registered trademarks or trademarks of the Apache Software Foundation in the United States and/or other countries. No endorsement by the Apache Software Foundation is implied by the use of these marks. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005181/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
